AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01534910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03175913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vapocoolant spray
Description: As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
Study NCT03175913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration
Description: As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
Study NCT00135135 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid
Description: See Detailed Description.
Study NCT00135135 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation therapy, Surgery, Peripheral Stem cell transplant
Description: See Detailed Description.
Study NCT03009006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
Study NCT03246217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Performance with Sensory-Enhanced Motor Imagery
Description: Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
Study NCT03009006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
Study NCT03009006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
Study NCT03009006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Hydroxide Paste - Non-Setting
Description: Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
Study NCT03246217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Performance with Motor Imagery
Description: Participants will engage in motor imagery of previously practised movements.
Study NCT02050308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-All Nations Breath of Life (I-ANBL)
Description: * Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~* Weekly procedures will follow the same format as for the first session
Study NCT02050308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Honoring the Gift of Heart Health
Description: These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities.
Study NCT02050308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®
Description: Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
Study NCT02050308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®
Description: Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
Study NCT02710149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD20-CAR-transduced T cells
Description: Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
Study NCT01986686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon resection
Description: Elective robotic/laparoscopic/open colon resection for diverticular disease.
Study NCT00987961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage
Description: This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
Study NCT02787941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered multifaceted intervention
Description: First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding.
Study NCT00740155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
Study NCT00740155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
Study NCT00740155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
Study NCT00740155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD-1,2,3,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
Study NCT00740155 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)
Description: 0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
Study NCT02667249 — intervention group
Intervention type: OTHER
Intervention: clinical pathway
Description: implementation of a standardized clinical pathway
Study NCT04669041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT04669041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT04669041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC ezetimibe/rosuvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT04669041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin active capsule
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study NCT04669041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT04669041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study NCT03514758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: several virtual 3-D complex audio environments
Description: The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
Study NCT00111956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT04650048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active HD-tDCS
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
Study NCT04650048 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham HD-tDCS
Description: Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS.
Study NCT04353830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI939
Description: Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
Study NCT04353830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI939+ Sintilimab
Description: IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit.
Study NCT04353830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI939+ Sintilimab
Description: IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit.
Study NCT00939042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: common Percutaneous Coronary Intervention
Study NCT00939042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMNC therapy
Description: Injection of BMNC after common PCI
Study NCT01581736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U100 Humulin
Description: Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
Study NCT01581736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Single episode of exercise riding a stationary bike.
Study NCT01256034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
Study NCT00711919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months.
Study NCT00711919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
Study NCT03308461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota suspension
Description: The prepared microbiota suspension was infused into mid-gut.
Study NCT04493242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
Study NCT04185480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
Study NCT02940626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN100
Description: monoclonal antibody combination of ASN-1 and ASN-2
Study NCT04493242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline
Description: Placebo
Study NCT01726530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal fentanyl patch (50 mcg/hour)
Study NCT01726530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01456819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear and mesenchymal stem cells
Description: Intramuscular administration into the ischemic limb
Study NCT01456819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mononuclear cells
Description: Intramuscular administration into the ischemic limb
Study NCT00111956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02940626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00982241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: drinking water / normal dietary fluids for oral intake
Study NCT02187900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)
Description: The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
Study NCT02187900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
Study NCT02717299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verasense
Description: Verasense will collect balancing data on all patients in this trial.
Study NCT02717299 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Verasense
Description: Verasense will collect balancing data on all patients in this trial.
Study NCT00079183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT02120313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inpatient rehabilitation
Study NCT02120313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: outpatient rehabilitation
Study NCT00993850 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy for insomnia
Description: Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
Study NCT02006667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
Study NCT02006667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
Study NCT03529643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Anesthesia with sevoflurane-remifentanil-dexmedetomidine
Study NCT03529643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without dexmedetomidine
Description: Anesthesia with sevoflurane-remifentanil
Study NCT02006667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
Study NCT02132234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: biological treatment according to rheumatologic indication
Study NCT02132234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: biological treatment according to rheumatologic indication
Study NCT02132234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Description: biological treatment according to rheumatologic indication
Study NCT02132234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: biological treatment according to rheumatologic indication
Study NCT02437448 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01503073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
Description: transcranial direct current stimulation
Study NCT01503073 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
Description: transcranial direct current stimulation
Study NCT04598581 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Radiation Therapy (LD-RT)
Description: Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
Study NCT04598581 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham irradiation
Description: Sham irradiation
Study NCT04213872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditative Movement
Description: The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
Study NCT02987764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cord milking
Description: For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
Study NCT02776657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
Study NCT02776657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
Study NCT00538291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00538291 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00538291 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Study NCT00538291 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Study NCT00538291 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00538291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00993850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bipolar education
Description: Psychoeducation